Zidovudine
Overview
Zidovudine is a synthetic dideoxynucleoside antiviral agent. It was first synthesized as an antineoplastic drug in the 1960s. In 1985, it was found to inhibit the in vitro infectivity of human immunodeficiency virus type-1 (HIV-1), although it was known to possess antiviral activity as early as 1974. Zidovudine is active against other retroviruses and some bacteria, but its sole indication is for the treatment and prevention of HIV infection in adults and children. On a weight basis, Zidovudine is more active than didanosine, but less active than zalcitabine, against HIV-1. It was approved by the FDA in March 1987.
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Zidovudine's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 2.857 mg/kg | 2.9 (2.857) | 8 hourly | PO | Initial |
| 3.571 to 4.286 mg/kg | 3.9 (3.9285) | 12 hourly | PO | Maintenance |
Paedriatic Dosage (20kg)
|
| 7.05 to 8.46 mg/kg | 7.8 (7.755) | 6 hourly | Oral | - |
Neonatal Dosage (3kg)
|
| 7.5 to 9 mg/kg | 8.2 (8.25) | 6 hourly | Oral | |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Zidovudine
Back to top
Previous Drug Generic - Next Drug Generic